Gimeracil (Compound)

Synonyms:Gimeracil, 103766-25-2, gimestat, 5-Chloro-2,4-dihydroxypyridine, 5-chloropyridine-2,4-diol, 5-Chloro-4-hydroxy-2(1H)-pyridone, 5-Chloro-4-hydroxy-2(1H)-pyridinone, Gimeracil [INN], 5-Chloro-4-hydroxy-1H-pyridin-2-one, 5-Chloro-2,4-pyridinediol, 5-chloro-2-hydroxypyridin-4(1H)-one, 2(1H)-Pyridinone, 5-chloro-4-hydroxy-, 5-CHLORO-4-HYDROXY-2-PYRIDONE, UA8SE1325T, DTXSID8046799, 5-CHLORO-4-HYDROXYPYRIDIN-2(1H)-ONE, MFCD08458352, 1349387-07-0, NCGC00181011-01, DTXCID6026799, Cdhp compound, CAS-103766-25-2, UNII-UA8SE1325T, Gimeracil (JAN/INN), GIMERACIL [JAN], GIMERACIL [MI], GIMERACIL [WHO-DD], GIMERACIL IMPURITY 1, GIMERACIL [EMA EPAR], SCHEMBL124438, Ts-1 (TN), CHEMBL1730601, Gimeracil, >=98% (HPLC), CHEBI:31652, AMY2406, TEYSUNO COMPONENT GIMERACIL, HMS3655B15, ACT04735, BCP05824, Tox21_112661, AC-475, STL452964, GIMERACIL COMPONENT OF TEYSUNO, AKOS006346735, AKOS015891515, AKOS026749993, Tox21_112661_1, BCP9000727, CCG-266172, CS-1822, DB09257, KS-5133, NCGC00181011-02, HY-17469, SY029154, C2243, FT-0645353, S2055, SW219483-1, D01846, AB01566858_01, EN300-3186161, A800802, A935098, SR-01000945072, Q-100034, SR-01000945072-1, 5-CHLORO-4-HYDROXY-1,2-DIHYDROPYRIDIN-2-ONE, Q22075887, Z1201624655
Pubchem:PUBCHEM:3472
Id:64a18885-bfc0-5c3f-ab71-a590371423f7
Description:nan

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View Gimeracil's neighborhood in the knowledge graph.

Gene and Drug Landing Page Aggegrator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for Gimeracil.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with Gimeracil.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.